Full Press Release Details
Updated as of.
INTS
Updated as of
Key Takeaway: Updated as of
Price reaction · baseline $7.7 (2026-03-04 close) · hit after-hours · 1 other INTS headline(s) in the window, move may be shared
day 0 close
+0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~12 mo
Medium dilution risk
Lead asset
INT230-6
Phase 3 · Sarcoma,Soft Tissue